论文部分内容阅读
多年来虽β—阻滞剂已成为治疗症状性肥厚型心肌病的首选药,但近期研究表明异搏定对本病有降低左室流出道梗阻、增大运动量和减轻症状的作用。本文报导78例肥厚型心肌病入出院继续长程服异搏定的临床疗效。
Although β-blockers have become the first choice for the treatment of symptomatic hypertrophic cardiomyopathy for many years, recent studies have shown that Verapamil has the effect of reducing left ventricular outflow tract obstruction, increasing exercise and alleviating symptoms. This article reports 78 cases of hypertrophic cardiomyopathy discharged into the hospital to continue long-distance service verapamil clinical efficacy.